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Abstract: The present report describes the improved ocu-
lar retention and aqueous humoral drug availability of 
ganciclovir (GCV) when administered via topical instil-
lation of different kind of nanoparticles onto the rabbit 
eye. GCV was loaded into PLGA nanoparticles, chitosan-
coated nanoparticles and chitosan-coated niosomal nano-
particles. All three formulations contained nanoparticles 
equally round in shape with a mean particle size in the 
range of 180–200 nm. The ocular corneal retention pro-
perty was evaluated by gamma scintigraphy, revealing 
that the clearance was slowest in the case of the chitosan-
containing formulations. GCV in chitosan-coated PLGA 
nanoparticles and chitosan-coated niosomal nanoparti-
cles showed approx. 6-fold higher aqueous humor drug 
availability as compared to a GCV solution and nearly 
2.5-fold higher as compared to the chitosan-lacking GCV-
PLGA nanoparticles. The results indicate that the use of 
a mucoadhesive chitosan coating can improve the ocular 
residence time and aqueous humoral availability of GCV 
when administered topically in nanoparticles.
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Introduction
Ganciclovir (GCV) is a synthetic acyclic nucleoside analog 
of 2′-deoxyguanosine, exhibiting antiviral activity against 
herpes simplex virus and cytomegalovirus at relatively 
low inhibitory concentrations [(IC50 of ∼50 to 500 ng/mL, 
respectively] (1, 2). GCV plays an important role in the 
treatment of ocular viral infections. Conventional treat-
ment involves the oral administration of GCV at a dose of 
3 g/day. However, this relatively high dose regimen is 
associated with the occurrence of side effects including 
bone marrow suppression and neutropenia (1, 3). Com-
pared to systemic treatment, intravitreal injection of 
GCV provides higher intraocular drug concentrations but 
repeated intravitreal injections are poorly tolerated (4). 
Topical ocular delivery of GCV is also an option, but its 
hydrophilic character and rapid elimination will result in 
poor intraocular availability of the drug. The tear film as 
well as the corneal and conjunctival epithelia represents 
a compact barrier hindering the absorption of topically 
applied hydrophilic drugs into the intraocular region. 
Therefore, topical delivery of GCV is associated with a 
low aqueous humor bioavailability (5–8). This limita-
tion encourages the development of mucoadhesive GCV 
nanoformulations for topical ocular delivery with the aim 
to attain a higher aqueous humoral availability allowing 
the administration of lower topical doses and reduction 
of dosing frequency. Thus, the objective of this work was 
to evaluate the topical ocular retention and increased 
intraocular delivery of GCV when administered topically 
entrapped in mucoadhesive nanoparticles as compared 
to topical ocular delivery of a GCV solution and nanopar-
ticles without mucoadhesive coating. In this study, PLGA 
nanoparticles and niosomes have been prepared and 
Brought to you by | Universiteit Twente
Authenticated
Download Date | 4/20/16 8:14 AM
160      Akhter et al.: Pharmacoscintigraphic and aqueous humoral drug availability of GCV nanoformulations
evaluated. PLGA, being a biodegradable, biocompatible 
and FDA-approved polymer as drug carrier and medical 
device is an obvious choice for topical ophthalmic for-
mulation. Moreover, niosomes have already been inves-
tigated as a potential topical ocular drug delivery system 
for many drugs categories such as antiglaucoma and anti-
biotics (9, 10).
These vesicles appear to be similar to liposomes in 
terms of their physical properties. They are also prepared 
in the same way and, under a variety of conditions, and 
form unilamellar or multilamellar structures. Niosomes 
have been claimed to alleviate some of the disadvantages 
associated with liposomes, such as relatively high cost 
(11). They also have the potential for controlled and tar-
geted drug delivery (9, 10).
Materials and methods
Chemicals
A gift sample of GCV was provided by Ranbaxy Laboratories Ltd. 
(Gurgaon, Haryana, India). Poly (lactide-co-glycolide) (PLGA, Re-
somer® 503H, lactic acid/glycolic acid, 50:50) was purchased from 
Boehringer Ingelheim (Germany). Chitosan (CS, high density, de-
acetylation degree  > 80%) was received as a gift sample from India 
Sea Foods, Cochin (India). Span 60 and cholesterol were purchased 
from S.D. Fine-chem Ltd. (Mumbai, India). Acetonitrile and trifluoro-
acetic acid (TFA) of HPLC grade were obtained from Qualigens Fine 
Chemicals (Mumbai, India). Water was produced in the laboratory by 
a Milli-Q purification system (Millipore, Billerica, MA, USA). All other 
reagents used were of analytical grade.
Preparation of GCV nanocarriers
Preparation of PLGA nanoparticles (GCV-NPs)
GCV-NPs were prepared by a double emulsion solvent evaporation 
method (12). Briefly, 100 μL of phosphate buffered saline (PBS; pH 
7.4) containing GCV (0.4% w/v) was emulsified in 1 mL dichlorometh-
ane containing 100  mg PLGA by sonication. The resulting primary 
emulsion was added to 20 mL of polyvinyl alcohol (PVA, 1.5% w/v in 
distilled water) with continuous stirring to form a double emulsion. 
The emulsion was stirred at 1500 rpm until complete evaporation of 
dichloromethane was achieved. The resulting nanosuspension was 
subjected to 3 cycles of homogenization at a pressure of 10,000 bar 
(EmulsiFlex-C5, Avestin, Inc., Canada). GCV-NPs were collected by 
centrifugation at 15,000 rpm for 10 min at 4°C, washed three times 
with distilled water, and Lyophilization was carried out in a freeze-
drier (Heto DRYWINNER, Germany) at 0.05  mBar for 24 h. The en-
trapment efficiency for the GCV in prepared formulation was then 
determined using the method reported by Duvvuri et al. (13) by UPLC 
quantification technique.
Preparation of chitosan-coated PLGA nanoparticles 
(GCV-CSNPs)
GCV-CSNPs were prepared using a water–oil–water (w/o/w) emul-
sion solvent evaporation method with slight modification (12). 
100 μL of PBS (pH 7.4) containing GCV (0.4% w/v) was emulsified 
in 1  mL dichloromethane containing 100  mg PLGA by sonication. 
The resulting primary emulsion was added to 20 mL of a mixed solu-
tion consisting of chitosan (CS) (0.25% w/v in 0.5 M acetate buffer, 
pH 4.4) and polyvinyl alcohol (PVA, 1.5% w/v in distilled water) with 
continuous stirring to form a double emulsion. The emulsion was 
stirred at 1500 rpm until complete evaporation of dichloromethane 
was achieved. The resulting nanosuspension was subjected to 3 cy-
cles of homogenization at a pressure of 10,000 bar (EmulsiFlex-C5, 
Avestin, Inc., Canada). GCV-CSNPs were collected by centrifugation 
at 15,000  rpm for 10  min at 4°C, washed three times with distilled 
water, and freeze-dried for 24 h. The entrapment efficiency for the 
GCV in prepared formulation was then determined using the method 
reported by Duvvuri et al. (13) by UPLC quantification technique.
Preparation of chitosan-coated niosomal nanoparticles 
(GCV-NDs)
GCV-NDs were prepared by the reverse-phase evaporation technique 
(1). Briefly, GCV-loaded niosomes were prepared by dissolving Span 
60 and cholesterol in the ratio of 3:2 w/w in diethyl ether and add-
ing 2 mL of PBS (pH 7.4) containing GCV. The mixture was sonicated 
for 5  min and a thick emulsion was obtained which was stirred at 
1500 rpm to remove any residual ether. To this emulsion 3 mL of PBS 
was added in order to hydrate the vesicles. The resulting vesicles 
were incubated for 2 h with a 0.2% w/w chitosan solution (in glacial 
acetic acid, 0.5% v/v, pH 5.5). GCV entrapment (%) was then estimat-
ed as per the method reported by Akhter et al. (1).
GCV quantification
GCV analysis was performed using a Waters Acquity ultra performance 
liquid chromatography (UPLC) system (Milford, MA, USA) equipped 
with a binary solvent manager, an autosampler, column manager 
composed of a column oven, a precolumn heater and a photo diode 
array detector. 5 μL of the final analytical solution was injected into a 
Waters Acquity second generation bridged ethyl hybrid (BEH) C18 (50 
mm × 2.1 mm, 1.7 μm) UPLC column kept at 50°C. The mobile phase 
consisted of a mixture of 0.1% TFA in water (adjusted to pH 3.5 using 
5.0% dilute ammonia) and acetonitrile (95:5, v/v). The flow rate was 
0.45 mL/min and detection was performed at a wavelength of 254 nm 
with total run time of 3 min. Data acquisition, data handling and in-
strument control were performed by Empower Software v1.0.
Characterization of GCV nanocarriers
Transmission electron microscopy
The surface morphology of the GCV nanoformulations was studied 
by transmission electron microscopy (TEM). Formulations treated on 
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copper grids (Polysciences, Warrington, PA) with 1% uranyl acetate 
for negative staining, followed by sample drying, were analyzed by 
TEM (Philips CM 10, The Netherlands) at an accelerating voltage of 
100 kV.
Particle size distribution and zeta potential
The mean particle size of the GCV nanoformulations was determined 
by photon correlation spectroscopy using a Zetasizer Nano ZS (Mal-
vern Instruments, Malvern, UK). For size determination, a sample 
of the dispersion was diluted to the appropriate concentration with 
Milli-Q water and analysis was performed at 25°C with an angle de-
tection of 90°. Zeta potential was measured using a disposable zeta 
cuvette with the same instrument.
In-vivo study
Ocular pharmacoscintigraphic and intraocular drug availabil-
ity experiments were carried out using New Zealand Albino rabbits 
(2.25 ± 0.25 kg). The study was carried out under the guidelines of 
CPCSEA (Committee for the Purpose of Control and Supervision of 
Experiments on Animals, Ministry of Culture, Government of India). 
The protocol was approved by the Institutional Animal Ethics Com-
mittee, Jamia Hamdard, New Delhi (approval no. 822) and the ARVO 
guidelines for animal usage were followed. Utmost care was taken to 
ensure that animals were treated in the most humane and ethically 
acceptable manner.
Ocular retention study: gamma-scintigraphy
The precorneal retention of nanoparticles after topical adminis-
tration was assessed by γ-scintigraphy. The radiolabeling of GCV 
loaded formulations were achieved by using 99mTc as per the proto-
col developed by Institute of Nuclear Medicine and Allied Sciences 
(INMAS), New Delhi, India (14). Labeling efficiency was determined 
using instantaneous thin layer chromatography (ITLC) and was 
found to be  > 98%. Corneal retention of chitosan-containing 99mTc-
labeled GCV-CSNPs and GCV-NDs were compared with chitosan-
lacking 99mTc labeled GCV-NPs. A total of 20 μL of the labeled for-
mulations were instilled into the cul-de-sac of the left eye of the 
rabbit, and the eye was manually blinked three times to distribute 
the formulation over the cornea. The right eye of each rabbit served 
as a negative control. A gamma camera (Millenium VG, Milwaukee, 
Wisconsin), autotuned to detect the 140 KeV radiation of Tc-99m, 
was used for the scintigraphy study. Rabbits were anesthetized by 
using a ketamine HCl injection given intramuscularly at a dose of 15 
mg/kg body weight and positioned 5 cm in front of the probe before 
the radio imaging. Recording was started 5 s after instillation and 
continued for 30 min using 128 × 128 pixel matrix. Sixty individual 
frames (60 × 30 s) were captured by dynamic imaging process. The 
region of interest (ROI) was selected on one frame of the image, and 
the time activity curve was plotted to calculate the rate of disap-
pearance from the eye surface. ROI activity of all the images were 
recorded on a computer system assisted with the software Entegra 
Version-2.
Ocular drug delivery study: aqueous humoral drug 
concentration profile
Four groups, each with seven New Zealand Albino rabbits 
(2.25 ± 0.25  kg), were used. The protocol was approved by the 
 Institutional  Animal Ethics Committee, Jamia Hamdard, New Delhi, 
India and corresponding guidelines were followed. Each group 
received, in both the eyes, a single topical instillation (50 μL) of GCV-
solution, GCV-NPs, GCV-CSNPs and GCV-NDs at a GCV dose equiva-
lent to 0.3% w/v of GCV (3 mg/mL). The eyes were anesthetized after 
the treatment using topical application of 4% xylocaine sterile so-
lution (AstraZeneca LP); 50 μL of the aqueous humor was collected 
using 30 gauze needles pre- and post-treatment at 0.5, 1, 2, 4, 6, 8 
and 12 h. All aqueous humor samples were collected in pre-labeled 
eppendorf tubes for UPLC analysis, sealed and stored at –20°C until 
UPLC analysis. The aqueous humor samples were prepared as men-
tioned above. Pharmacokinetic parameters (PK) were calculated by 
non-compartmental analysis (model independent analysis using 
WinNonLin version 4.0 (Pharsight Corp., Mountain View, CA, USA).
Sample preparation
All the rabbit aqueous humor samples were stored at –20°C and al-
lowed to thaw at room temperature prior to sample preparation. A 
50 μL aliquot of rabbit aqueous humor was pipetted into a 1.0 mL 
eppendorf tube, followed by the addition of 100 μL of acetonitrile. 
The samples were vortexed for 5 min followed by 5 min of centrifu-
gation at 10,000 rpm. The samples were filtered through a 0.22 μm 
nylon filter and 5 μL of the filtrate was directly injected into the 
UPLC system
Ocular tolerance test
The potential ocular irritancy of GCV-NPs, GCV-CSNPs and GCV-NDs 
were evaluated according to a modified Draize test (15) using a slit-
lamp. The congestion, redness and swelling, and tear discharge of 
the conjunctiva were graded on a scale from 0 to 3, 0 to 4, and 0 to 
3, respectively. Nanoparticles (50 μL) were topically applied in the 
right eye (every 10 min for 1 h) and the left eyes were used as controls. 
Observation of the ocular tissue condition was performed at 12 h and 
24 h after the end of the experiments.
Results and discussion
Preparation and characterization of GCV 
nanocarriers
We designed PLGA- and Span-based nanoparticles 
(niosomes) coated with a chitosan coating to increase the 
mucoadhesivness and as a result the retention time after 
instillation onto the eye cornea was improved. The mean of 
GCV entrapment (%) in GCV-NPs, GCV-CSNPs and GCV-NDs 
were 49.3%, 46.7% and 47.2%, respectively. The TEM and 
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A B C
Figure 1 Transmission electron microphotographs of GCV nanoparticles: (A) GCV-NPs (reference), (B) chitosan-coated GCV-CSNPs, and 
(C) chitosan-coated GCV-NDs.
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Figure 2 Particle size distribution of GCV nanoparticles: (A) reference GCV-NPs, (B) chitosan- coated GCV-CSNPs, and (C) chitosan-coated 
GCV-NDs.
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the particle size distribution of the GCV nanoformulations 
are shown in Figures 1 and 2, respectively. The micrographs 
of the chitosan-coated GCV-CSNPs and GCV-NDs demon-
strated a very different appearance as compared to the 
reference GCV-NPs (Figure 1B and C). Spherical-shaped par-
ticles with a double layer structure were observed in case of 
chitosan-coated nanoformulations indicating the existence 
of chitosan surrounding the GCV-CSNPs and GCV-NDs. 
The hydrophilic polymer coating of PLGA and surfactant 
based nanoparticles would depend on the capability of the 
polymer to adhere to the hydrophobic layer. The interaction 
between chitosan and such particles surface area due to a 
combination of physical adsorption, hydrophobic interac-
tion and bridging between them. In general, all of the three 
formulations, GCV-NPs, GCV-NDs, and GCV-CSNPs were 
equally round in shape with a mean particle size in the 
range of 180–200 nm (Figure 2). The polydispersity index 
(PI), which is a measure of uniformity of size within the for-
mulation (1, 16), was also measured. The GCV-NDs exhib-
ited a more narrow size distribution (PI, 0.181) compared to 
GCV-CSNPs (PI, 0.65) and GCV-NPs (PI, 1.15), with a mean 
size of 190 nm, 200 nm and 190 nm, respectively. The zeta 
potential of GCV-NPs, GCV-NDs, and GCV-CSNPs were –23.4 
mV, +41.8 mV and +37.2 mV, respectively. The zeta potential 
is an important particle characteristic indicating the surface 
charge that can influence the nano-suspension as well as 
the mucoadhesion into the ocular surface. The electro-
static charge repulsion between the similar charge (either 
positive or negative) particles prevents the aggregation and 
thus ensure the dispersed state of the nanosuspension. On 
the other hand, positive surface charge (illustrate by posi-
tive zeta potential value) on the particles is responsible for 
mucoadhesion with mucin layer. In the present study, posi-
tive value zeta potential of GCV-NDs, and GCV-CSNPs pro-
vided the proof of successful chitosan adsorbed cationic 
surface modification of niosomes and GCV-NPs. Moreover, 
all the three formulations showed good dispersion stability.
Rabbit studies
Ocular retention
Gamma-scintigraphy is a well-established technique 
for the in-vivo monitoring of the fate of nanocarriers 
(14). After administration of the radiolabeled ophthal-
mic formulation, a good spreading was observed over 
the entire precorneal area. The quantification of radio-
activity in ROIs enabled the assessment of the remain-
ing acti vity at different time points after instillation. 
Radioacti vity values counted in the ROI on gamma 
scintigraphic dynamic whole body images collected for 
the first 30  min after administration of the reference 
(chitosan lacking) and chitosan-coated formulations 
(radioactivity versus time profile) is shown in Figure 
3. As expected, the clearance of the reference (chitosan 
lacking) PLGA nanoparticles (GCV-NPs) from the ocular 
surface was most rapid. This can be explained by the 
lack of mucoadhesion with the cornea. In contrast, the 
chitosan-containing GCV-CSNPs and GCV-NDs were 
retained on the ocular surface significantly longer 
(p < 0.05) than GCV-NPs (Figure 3A–C). The AUC0–30 min 
for the retained activity of GCV-CSNPs and GCV-NDs 
were 47,505 and 39,431, respectively, which is about 
4-fold higher as compared to the reference GCV-NPs 
with a value of 11,032. These findings advocate that 
the presence of chitosan in the formulations serves 
to prolong the retention of the nanoparticles on the 
corneal surface. Particularly, due to the interaction of 
positively charged chitosan with the cornea surface 
which is negatively charged by the pre sence of mucin 
and other components (4, 7). Moreover, the uniform 
and spherical large surface area increased the spread-
ing and contact time of the mucoadhesive nanoparti-
cles over the corneal surface thereby promoting the 
corneal retention (17).
Figure 3 Pre-corneal retention of 99mTc- labeled formulations after single topical instillation of: (A) reference GCV-NPs, (B) chitosan-
coated GCV-CSNPs, and (C) chitosan-coated GCV-NDs.
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Intraocular aqueous humoral drug delivery
Aqueous humor GCV concentration-time profiles upon 
topical instillation of GCV solution, GCV-CSNPs, GCV-NPs 
and GCV-NDs to the rabbit eye are shown in Figure 4. 
 Calculated kinetic parameters are shown in Table 1. In 
the group treated with the GCV solution, a relatively 
low ocular bioavailability (AUC0-t, 495 ± 11 ng·h/mL) 
was observed; the aqueous humor levels of the drug 
were undetectable after 2 h, which can be attributed to 
rapid pre-corneal loss. Administration of the reference, 
chitosan-lacking GCV-NP formulation yielded an about 
3-fold higher value (1361.4 ± 12.0 ng·h/mL) compared to 
the GCV solution indicating that incorporation in nano-
sized PLGA particles can improve the permeation by 
improving corneal retention (12, 17). Topical instillation 
of GCV-CSNPs and GCV-NDs even more enhanced the 
humoral drug concentration with nearly similar avail-
ability of 3991 ± 20 and 3428 ± 29 ng·h/mL, respectively. 
The humoral drug availability was approx. 7- to 8-fold 
higher as compared to the GCV solution and approx 
2.5-fold higher as compared to the reference GCV-NPs. 
Our results indicate that both chitosan-coated GCV 
Table 1 Topical instillation of GCV solution and GCV nanoparticles onto the rabbit eye: pharmacokinetic parameters.
Parameter GCV-sol GCV-NPs GCV-CSNPs GCV-NDs
atmax (h) 0.9 ± 0.03 1.0 ± 0.05 1.4 ± 0.07 1.0 ± 0.04
aCmax (ng/mL) 325 ± 5.1 589 ± 8.9 449 ± 6.5 523 ± 8.2
aKe (1/h) 1.50 ± 0.11 0.67 ± 0.08 0.08 ± 0.01 0.13 ± 0.02
aAUC0–t (ng·h/mL) 495.1 ± 11.3 1361.4 ± 12.0 3991.3 ± 20.1 3428.1 ± 29.4
aAUC0–∞ (ng·h/mL) 720.5 ± 19.6 1528.3 ± 20.70 5622.1 ± 39.5 4160.7 ± 46.9
aMean values ± SD (n = 14; both eyes of each rabbit out of the seven rabbits were used).
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Figure 4 Aqueous humor concentration–time profile of GCV after 
topical instillation of GCV- solution, reference GCV-NPs, chitosan-
coated GCV-CSNPs and chitosan-coated GCV-NDs onto the rabbit 
eye.
nanoparticle formulations provided higher aqueous 
humoral drug availability as compared to a GCV solu-
tion and the chitosan-lacking reference nanoparticles. 
This can be attributed to an increased corneal retention 
of the GCV nanoformulations, providing a larger time 
frame for sustained release of the entrapped drug. Fur-
thermore, the large surface area provided by nanosized 
particles increased the spreading and contact time over 
the corneal surface which favours the corneal reten-
tion. Clearly, the significantly increased corneal reten-
tion mediated by the mucoadhesiveness conferred by 
chitosan contributes strongly to the improvement of the 
transcorneal drug permeation (7, 17).
Ocular tolerance study
For such a nanometric delivery system to be proposed as 
an ophthalmic nanomedicine, it is important not only to 
examine the biopharmaceutical properties but also their 
non-irritant nature. Therefore, in-vivo ocular irritation test 
for GCV-NP, GCV-CSNPs, GCV-NDs were evaluated by using 
modified Draize test. The in-vivo result of ocular irritation 
test in rabbits showed no visual sign of irritation or other 
tissue damaging effect to anterior ocular tissues (data 
were not given). Moreover, there were no excessive tear 
formation and the clinical scores for conjunctival swell-
ing, corneal opacity and discharge were always zero in the 
case of treatment group of all the formulation during the 
study phase. The results confirmed that the studied for-
mulations were non-irritant and well tolerated.
Conclusion
Entrapment of GCV in PLGA nanoparticles and niosomes 
increases the GCV concentration in the aqueous humor. 
Coating of the surface of the nanoparticles with chitosan 
further promotes the corneal drug absorption process by 
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virtue of an increased retention on the ocular surface. 
Therefore, we propose that chitosan-coated nanoparticles 
are promising carriers for GCV in novel topical ophthalmic 
nanoformulations.
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